Feng Gang, Gao Jia-Lin, Zhang Peng, Huang Jian-Jun, Huang Li-Zhu, Cheng Long, Pu Chun
Clinical Laboratory, The First Affiliated Hospital of Wanan Medical College, Wuhu, 241001, Anhui, China.
Department of Endocrinology and Genetic Metabolism, The First Affiliated Hospital of Wanan Medical College, Wuhu, 241001, Anhui, China.
Acta Diabetol. 2017 Nov;54(11):1047-1055. doi: 10.1007/s00592-017-1048-0. Epub 2017 Sep 12.
The aim of this study was to determine the activity of serum extracellular superoxide dismutase (ecSOD) in patients with type 2 diabetes mellitus (T2DM) and healthy subjects, and to determine the prospective association between baseline serum ecSOD activity and the subsequent risk of albuminuria progression in a cohort of Chinese T2DM patients.
A total of 458 T2DM patients and 100 healthy subjects were assessed. After a median follow-up of 7.7 months, 319 patients with baseline normoalbuminuria (urinary albumin-to-creatinine ratio [UACR] <30 mg/g) and 77 patients with baseline microalbuminuria (UACR = 30-299 mg/g) were divided into progression and non-progression groups according to UACR changes. Serum ecSOD activity was determined by the autoxidation of pyrogallol method. Multivariate Cox regression analysis was used for investigating the predictors for albuminuria progression.
Compared with healthy controls (174.5 ± 25.1 U/mL), serum ecSOD activity significantly decreased in T2DM patients with normoalbuminuria (114.9 ± 13.2 U/mL), with microalbuminuria (106.6 ± 16.3 U/mL), and with macroalbuminuria (97.1 ± 18.2 U/mL) (all P < 0.001). Serum ecSOD activity was associated with albuminuria (odds ratio [OR] = 1.028, P = 0.004) in T2DM patients. Baseline serum ecSOD activity (hazard ratio [HR] = 0.902, 95% CI 0.877-0.928, P < 0.001) was an independent predictor for albuminuria progression.
Serum ecSOD activity may be useful for predicting the future risk of albuminuria progression in Chinese T2DM patients.
本研究旨在测定2型糖尿病（T2DM）患者和健康受试者血清细胞外超氧化物歧化酶（ecSOD）的活性，并确定中国T2DM患者队列中基线血清ecSOD活性与随后蛋白尿进展风险之间的前瞻性关联。
共评估了458例T2DM患者和100名健康受试者。在中位随访7.7个月后，根据尿白蛋白肌酐比值（UACR）变化，将319例基线正常白蛋白尿（UACR<30mg/g）患者和77例基线微量白蛋白尿（UACR=30-299mg/g）患者分为进展组和非进展组。采用邻苯三酚自氧化法测定血清ecSOD活性。多因素Cox回归分析用于研究蛋白尿进展的预测因素。
与健康对照组（174.5±25.1U/mL）相比，正常白蛋白尿的T2DM患者（114.9±13.2U/mL）、微量白蛋白尿患者（106.6±16.3U/mL）和大量白蛋白尿患者（97.1±18.2U/mL）的血清ecSOD活性均显著降低（均P<0.001）。T2DM患者血清ecSOD活性与蛋白尿相关（比值比[OR]=1.028，P=0.004）。基线血清ecSOD活性（风险比[HR]=0.902，95%CI 0.877-0.928，P<0.001）是蛋白尿进展的独立预测因素。
血清ecSOD活性可能有助于预测中国T2DM患者未来蛋白尿进展的风险。
